Caplyta

Chemical Namelumateperone
Dosage FormCapsule (oral; 42 mg)
Drug ClassAntipsychotics
SystemNervous
CompanyIntra-Cellular Therapies
Approval Year2019

Indication

  • Caplyta is indicated for the treatment of schizophrenia in adults.
Last updated on 10/30/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Caplyta (lumateperone) Prescribing Information2019Intra-Cellular Therapies